George Hajjar

Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.

Malik E. Juweid, Edward A. Stadtmauer, George Hajjar et al. · PubMed · 1999 · 119 citations

Pharmacy, Oncology, Pharmacokinetics +17

Perioperative ischaemia in aortic surgery: combined epidural/ general anaesthesia and epidural analgesia vs general anaesthesia andiv analgesia

R. L. Garnett, Annette MacIntyre, Patrice Lindsay et al. · Canadian Journal of Anesthesia/Journal canadien d anesthésie · 1996 · 105 citations

Medicine, Perioperative Medicine, Surgery +11

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Robert M. Sharkey, A. J. Brenner, J. D. Burton et al. · PubMed · 2003 · 92 citations

Medicine, Oncology, Pharmacology +17

Phase I/II trial of131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

Malik E. Juweid, George Hajjar, Lawrence C. Swayne et al. · Cancer · 1999 · 83 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.

Malik Juweid, George Hajjar, Rhona Stein et al. · PubMed · 2000 · 71 citations

Medicine, Nuclear Medicine, Oncology +17